CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 404086-404160 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T52086","span":{"begin":0,"end":74},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In EAE, targeting of VAP-1 with a VAP-1 antibody reduced disease activity."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T49","span":{"begin":0,"end":74},"obj":"Sentence"}],"text":"In EAE, targeting of VAP-1 with a VAP-1 antibody reduced disease activity."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T874","span":{"begin":3,"end":6},"obj":"Phenotype"}],"attributes":[{"id":"A874","pred":"hp_id","subj":"T874","obj":"http://purl.obolibrary.org/obo/HP_0002383"}],"text":"In EAE, targeting of VAP-1 with a VAP-1 antibody reduced disease activity."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T2591","span":{"begin":3,"end":6},"obj":"Disease"},{"id":"T99700","span":{"begin":3,"end":6},"obj":"Disease"}],"attributes":[{"id":"A2591","pred":"mondo_id","subj":"T2591","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A2592","pred":"mondo_id","subj":"T2591","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A2593","pred":"mondo_id","subj":"T2591","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A46295","pred":"mondo_id","subj":"T99700","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A63316","pred":"mondo_id","subj":"T99700","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A8446","pred":"mondo_id","subj":"T99700","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"}],"text":"In EAE, targeting of VAP-1 with a VAP-1 antibody reduced disease activity."}